More recently, there are reports of longer survival in patients with certain breast cancer subtypes with LMD, including those with HER2 positive MBC in which treatment with intrathecal (IT) HER2-directed therapies such as trastuzumab has resulted in median survival of closer to 12 months5,6. This evidence concerns the gene ERBB2 and breast carcinoma.